Antihypertensive monopharmacotherapy with diuretics renders blood pressure (BP) values under control in a large percentage of patients suffering from essential hypertension, and it reduces cardiovascular morbidity and mortality. Diuretics are effective in adult and elderly hypertensive subjects, independently of their race. Treatments with classic (high) doses of antihypertensive diuretics, such as 25 mg hydrochlorothiazide once daily, raise the activity of the RAA system, decrease plasma potassium and magnesium concentrations, and cause untoward changes in carbohydrate metabolism and in the plasma lipid profile. These changes appear to limit the positive response of cardiovascular prognosis to antihypertensive therapy with classic doses of diuretics. Lower doses of diuretics reduce high BP to the sought extent in many patients, and they do not
Introduction
Diuretics are in the forefront of the antihypertensive armamentarium and constitute the reference antihypertensive drugs. This is so because monopharmacotherapy with these substances lowers high blood pressure (BP) to acceptable levels in many patients who suffer from mild-to-moderate uncomplicated essential hypertension, and because the decrease in BP induced by diuretics entails an important reduction in cardiovascular risk. 1 The beneficial effects of diuretics on high BP and on cardiovascular risk hold in adult and in elderly patients, 2 irrespective of the race. Effective once-daily treatment with a diuretic controls high BP over 24 h.
The range of effectively antihypertensive doses of diuretics
The beneficial actions of effective antihypertensive therapy with diuretics on cardiovascular prognosis notwithstanding, these substances elicit dosedependent neuroendocrine, biochemical and metabolic responses that oppose the beneficial effect that the diminution in BP has on cardiovascular risk. 3, 4 These untoward effects of diuretics include decreases in the serum concentrations of potassium and magnesium, untoward changes in carbohydrate metabolism (reduction in glucose tolerance) and in the plasma lipid profile (increases in plasma cholesterol and in plasma triglyceride concentrations), an increase in the serum concentration of uric acid, an increase in the activity of the renin-angiotensinaldosterone (RAA) System, a decrease in the production of natriuretic peptides and, in certain cases, an increase in the plasma concentration of vasopressin. 5 
Importance of the dose
The antihypertensive and unfavourable effects of diuretics increase as functions of the dose. However, the maximal antihypertensive action of diuretics occurs at a dose that is lower than the doses that cause maximal unwanted effects. Thus, doses above the dose that is maximally effective in terms of BP reduction provoke more intense unwanted neuroendocrine and metabolic changes and thereby reduce the beneficial effect that the decrease in BP has on hypertension-associated cardiovascular risk.
The unwanted pharmacological actions of common thiazide-type and loop diuretics are increasing functions of the natriuretic response to these substances, ie appreciable variations in the unfavourable neuroendocrine and metabolic responses to common diuretics and in the renal excretory effects of these drugs share their dose-dependence range. This holds for the unwanted actions of diuretics that bear a well-known functional relationship with S79 forced natriuresis (eg, the rise in the activity of the RAA System) and for the undesired effects whose functional link with increased renal sodium excretion, if any, has not been established (eg, the reduction in glucose tolerance). For this reason, the magnitude of the natriuretic response to the oral formulations of diuretics used to treat hypertension is taken as a broad overall indicator of the magnitude of the unwanted effects of these medications.
High-dose formulations of diuretics
Hydrochlorothiazide 25 mg is considered a highdose formulation of a diuretic, since mean 24-h natriuresis increases by more than 40% in response to a single dose or to the first once-daily dose of this antihypertensive preparation in certain reference clinicoexperimental circumstances (Figure 1 ). [5] [6] [7] [8] This increase in natriuresis wanes in a few days (established 'braking phenomenon') 5 in healthy subjects ( Figure 1 ), due to the action of reactive functional changes that tend to preserve bodily sodium. Some of the processes that conserve sodium, including an elevation in the activity of the RAA System, also augment renal potassium excretion and therefore keep 24-h kaliuresis elevated after 24-h natriuresis is no longer increased in the course of oncedaily treatment with hydrochlorothiazide 25 mg ( Figure 1 ). Thus, high-dose diuretics reduce serum potassium concentration. Hypokalaemia offsets the cardiovascular benefit conferred by the reduction in high BP caused by diuretics. 9 In addition to hydrochlorothiazide 25 mg, the set of formally defined Figure 1 Eleven healthy subjects staying in a metabolic unit took once-daily oral doses of placebo and of hydrochlorothiazide 25 mg, at 08.00 hours, during two conveniently separated singletreatment periods of 4 days each. An individually randomised, crossover and double-blind design was followed. Adapted from numerical results published in Leary et al 6 ; figure reproduced from Reyes, 7 by courtesy of Monduzzi Editore.
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high-dose antihypertensive formulations of diuretics includes clopamide 5 mg, indapamide 2.5 mg, xipamide 10 and 20 mg, and hydrochlorothiazide 50 mg. 
Low-dose formulations of diuretics
The expression 'low-dose', as usually applied to amounts or formulations of diuretics that constitute efficacious once-daily antihypertensive monopharmacotherapies, encompasses very-low, low and lower doses.
A single dose or the first once-daily dose of lowdose formulations of diuretics, such as torasemide 5 mg (Figure 2 ) or cicletanine 50 mg, 5 increase 24-h natriuresis by less than 40%. On average, low-dose formulations of diuretics do not raise the activity of the RAA System to a considerable extent, and they do not increase 24-h kaliuresis ( Figure 2 ) upon prolonged treatment. 5 Very-low-dose formulations of diuretics do not elevate 24-h natriuresis in healthy subjects. 5 Torasemide 2.5 mg, which is a very-low-dose formulation (Figure 2 ), has practically no effect on the activity of the RAA System, and it does not change the magnitude of the 24-h renal excretions of chloride, potassium, calcium, magnesium, and zinc. [10] [11] [12] Several oral formulations of classic diuretics, such as bendrofluazide 1.25 mg, [13] [14] [15] chlorthalidone Figure 2 Partial results of a study in which 16 healthy subjects staying in a metabolic unit took once-daily oral doses of placebo and of torasemide 2.5, 5 and 10 mg, at 08.00 hours, during four conveniently separated single-treatment periods of 7 days each. An individually randomised, crossover and double-blind design was followed. From AJ Reyes, WP Leary and K van der Byl: unpublished study.
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Antihypertensive action of low-dose formulations of diuretics
The decrease in BP caused by monopharmacotherapy with low-dose formulations of diuretics taken once daily progresses slower over the first weeks of treatment than the reductions caused by high-dose formulations ( Figure 3 ). The response of BP to monopharmacotherapy with a low dose of a diuretic should not be considered complete until 12-14 weeks have elapsed after the initiation of treatment. Smooth decreases in BP over the first weeks of treatment could be better tolerated than quick reductions by patients with impaired circulation in certain vascular circuits.
The circadian rhythm of BP is not affected by efficacious antihypertensive monopharmacotherapy with a low dose of a diuretic.
15,35

Safety of diuretics at low doses
Antihypertensive treatment with a low dose of a diuretic has little effect on serum potassium and magnesium concentrations, on fasting glucose and on plasma cholesterol fractions. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [36] [37] [38] [39] [40] [41] [42] The only biochemical variable that is affected by most antihypertensive diuretics irrespective of the dose is serum uric acid concentration, which undergoes a small increase, on average, even when low doses are used. 13, 21, 43 Cicletanine 50 mg does not modify the renal handling of urate, 44 and it does not elevate serum uric acid concentration.
37,44
Prescribing diuretics for hypertension
Antihypertensive pharmacotherapy may be started with a diuretic in patients who present mild-tomoderate uncomplicated essential hypertension, provided that no contraindication exists and that there is no compelling indication for a drug of a different pharmacological class. Some antihypertensive diuretic substances and the initial doses at which they should be used to treat hypertension are listed in Table 1 .
High sodium intakes and certain medicines that tend to make external sodium balance positive, such as non-steroidal inflammatory drugs and corticosteroids, may attenuate or blunt the antihypertensive effect of diuretics.
When BP has not decreased to the sought extent in response to 12-14 weeks of monopharmacotherapy with a diuretic at the doses quoted in Table 1 , despite good compliance with dietary and pharmacological prescriptions and in the absence of factors-such as certain co-medications-that might have attenuated the response of BP, the dose of the diuretic may be augmented if the substance used has been well tolerated. However, the alternative of adding a drug of a different pharmacological class instead of increasing the dose of the diuretic should be considered in these circumstances, in-so-far as escalating the dose elevates the intensity of the unfavourable neuroendocrine and metabolic actions of diuretics. Diuretics should be prescribed to patients in whom antihypertensive therapy with a drug of a different class has not reduced BP satisfactorily, when it is decided to add a second drug and provided no contraindication exists. Diuretics should substitute for ineffectual antihypertensive drugs of a different class.
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Diuretics may be used in patients with type 2 diabetes, since they reduce cardiovascular risk in these patients when they lower high BP effectively. [47] [48] [49] However, diuretics affect carbohydrate metabolism untowardly 5 in dose-dependent fashion and therefore the doses quoted in Table 1 should not be surpassed in patients with mild-to-moderate hypertension and type 2 diabetes.
In patients with advanced renal insufficiency, high BP usually has the expansion of extracellular volume as its main determinant. These cases should be treated with a loop diuretic at a dose that increases natriuresis.
Combinations of diuretics
When low doses of diuretics are used, there is usually no need to add a potassium-retaining diuretic, such as amiloride, to the therapeutic regimen to prevent hypokalaemia. Available fixed-dose combinations of a thiazide and a potassium-retaining diuretic should not be used to treat uncomplicated essential hypertension since they may cause hyponatraemia, particularly in elderly women. 50 Fixed-dose combinations of a diuretic and an antihypertensive substance of another class are justified when the amount of each active moiety is not an efficacious once-daily antihypertensive per se but contributes to the effective action of the combination, and provided the combined drugs do not concur to the production of undesired effects. Thus, pharmacological unwanted actions are minimised. The combination of 0.625 mg of the diuretic indapamide and of 2 mg of the ACE inhibitor perindopril
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constitutes an example of an adequate fixed-dose combination of antihypertensive drugs for the firstline treatment of mild-to-moderate uncomplicated essential hypertension. This is so because oncedaily antihypertensive therapy with this combination lowers high BP effectively, [51] [52] [53] whereas the diuretic indapamide at 0.625 mg once daily may be assumed not to be efficacious 54, 55 and the 2 mg preparation of perindopril does not meet the criteria that would permit to qualify it as an effective once-daily antihypertensive formulation. 56 
Future research
The responses of cardiovascular prognosis to effective control of high BP with the low doses of diuretics quoted in Table 1 and with slightly higher doses of the same substances should be subjected to comprehensive investigative scrutiny.
The responses of cardiovascular prognosis to attainment of target BP values by increasing the initial doses of diuretics quoted in Table 1 and by adding a drug of a different pharmacological class, when the response of BP to the initial doses of diuretics is insufficient, should be contrasted in formal research endeavours.
